Open an account

Lyell Immunopharma

LYEL · NASDAQ

$9.70+$0.90 (+10.23%)TodayMarket closed ·
Prev close $8.80

About LYEL

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 161 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Employees
161
Headquarters
South San Francisco, California
Listed
Jun 17, 2021
Sector
Health Care
Industry
Biotechnology
Website
lyell.com

LYEL key statistics

Market cap
237.70M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
173.69K
Volume
158.63K
Open price
$8.74
High today
$10.01
Low today
$8.57
52 Week high
$45.00
52 Week low
$7.20

Lyell Immunopharma (LYEL) at a glance

As of Oct 20, 2026, Lyell Immunopharma (LYEL) shares are priced at $9.70, giving the company a market cap of 237.70M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.57 and $10.01. The current price is 13.3% above the day's low and 3.1% below its high.

Volume so far is 158.63K shares, in line with the average of 173.69K shares a day.

Over the past year Lyell Immunopharma has ranged from $7.20 to $45.00, and now sits 7% of the way up that range.

Lyell Immunopharma met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.92 per share against an estimate of -$2.06.

The average analyst price target is $38.63, 298.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $38.63
Low
$12.12
Now
$9.70
High
$51.45

LYEL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 20.5% on average.

  1. Q3 FY24: reported -$3.40 per share against an estimate of -$4.08
  2. Q4 FY24: reported -$4.00 per share against an estimate of -$3.47
  3. Q1 FY25: reported -$3.54 per share against an estimate of -$3.67
  4. Q2 FY25: reported -$2.89 per share against an estimate of -$3.65
  5. Q3 FY25: reported -$2.13 per share against an estimate of -$2.70
  6. Q4 FY25: reported -$7.50 per share against an estimate of -$2.28
  7. Q1 FY26: reported -$1.10 per share against an estimate of -$2.41
  8. Q2 FY26: reported -$1.92 per share against an estimate of -$2.06

LYEL news

  • Vandana Singh

    Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update

  • Press releaseGlobe Newswire

    Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

  • Press releasePRNewswire

    Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releasePRNewswire

    Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Similar companies

Companies in the same industry as Lyell Immunopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.